We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genincode Plc | LSE:GENI | London | Ordinary Share | GB00BL97B504 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.25 | 48,297 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2.00 | 2.50 | 2.25 | 2.25 | 2.25 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 2.7M | -4.43M | -0.0155 | -1.45 | 6.45M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:46:59 | O | 60 | 2.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/6/2025 | 11:30 | ALNC |  GENinCode shares surge as loss narrows amid increased revenue |
| 04/6/2025 | 07:00 | UK RNS | GENinCode PLC Final Results |
| 16/5/2025 | 07:00 | UK RNS | GENinCode PLC Notice of Results |
| 30/4/2025 | 07:00 | UK RNS | GENinCode PLC De Novo Submission Update |
| 26/3/2025 | 07:45 | UK RNS | GENinCode PLC Grant of Share Options & PDMR Dealings |
| 06/3/2025 | 14:24 | UK RNS | GENinCode PLC Holding(s) in Company |
| 05/3/2025 | 15:02 | UK RNS | GENinCode PLC Holding(s) in Company |
| 04/3/2025 | 13:16 | UK RNS | GENinCode PLC Holding(s) in Company |
| 03/3/2025 | 12:54 | UK RNS | GENinCode PLC Result of General Meeting, Issue of Equity and TVR |
| 18/2/2025 | 07:00 | UK RNS | GENinCode PLC Result of Retail Offer |
Genincode (GENI) Share Charts1 Year Genincode Chart |
|
1 Month Genincode Chart |
Intraday Genincode Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:47:00 | 2.00 | 60 | 1.20 | O |
| 09:47:00 | 2.50 | 5,000 | 125.00 | O |
| 09:47:00 | 2.00 | 1,200 | 24.00 | O |
| 09:16:17 | 2.40 | 64 | 1.54 | O |
| 09:15:33 | 2.40 | 333 | 7.99 | O |
| Top Posts |
|---|
Posted at 18/6/2025 09:20 by Genincode Daily Update Genincode Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENI. The last closing price for Genincode was 2.25p.Genincode currently has 286,882,042 shares in issue. The market capitalisation of Genincode is £6,454,846. Genincode has a price to earnings ratio (PE ratio) of -1.45. This morning GENI shares opened at 2.25p |
Posted at 17/6/2025 06:48 by kingston78 It is time to double up because the share is going to spring like a coil from a low base. The share price will double to 4 p soon. |
Posted at 16/6/2025 08:26 by kingston78 The recent price action is to break the 2.2 p level. Once broken, it will spike to 6 p on good news. |
Posted at 05/6/2025 09:21 by fillipe GENI - recently being well bought at 2.5p ....lowest ASK on show now 2.7p.A nice climber with a great target price. f |
Posted at 07/5/2025 14:48 by pk83 Such a screaming price to gamble at here. 60% cheaper than the last raise. They iron out the FDA issues which they say they can albeit no guarantee. There's 10 x in this from this price on FDA approval |
Posted at 18/3/2025 22:25 by horneblower This dog of a share has potential, if only from the chart pattern, which suggests a return to 8.5p to 10p.Perhaps some local can say why? |
Posted at 14/2/2025 11:10 by toffeeman I have applied - to try and get my average price below 9p! |
Posted at 11/2/2025 18:06 by shearluc Huge fan of GENI, and they will do very well, but surely they are running very low on cash right now? |
Posted at 23/1/2025 08:25 by z1co Share price could easily RISE over 200% just like EXR did yesterday |
Posted at 15/12/2021 14:57 by hedgehog 100 At just 33.5p the GENI share price is getting a bit silly now.The IPO on 22nd. July was at 44p, and that looked a bargain. Since when there has been steady progress. I'm a big fan of 'overhang plays', because when the supply of cheap shares dries up, the share price can rebound quite dramatically, which is what I fully expect to happen here. |
Posted at 31/10/2021 12:09 by hedgehog 100 22/07/2021 07:00 UK Regulatory (RNS & others) GENinCode PLC Admission to trading on AIM & First Day of Dealing LSE:GENI Genincode Plc"... On 28 April 2021, the Company announced a partnership to provide genetic testing from labs based at Royal Brompton and Harefield Hospitals. Following this, it was announced on 14 June 2021 that a product commercialisation agreement had been entered into with EVERSANA in the US. The Directors believe that the partnership with EVERSANA, a leading provider of global commercial services to the life science industry, will provide a significant opportunity for the Group to progress its commercialisation plans for the US. ..." "GENinCode announces major US commercialisation partnership with EVERSANA Posted on June 14, 2021 Oxford, UK. — 14, June 2021 — GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC (“EVERSANA&rdq EVERSANA is a leading provider of global commercial services to the life sciences industry. In the United States, GENinCode will utilise EVERSANA’s COMPLETE Commercialisation model fully integrating services that include market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, health economics and outcomes research and compliance, with each service optimised by data and predictive analytics. The suite of expertise will underpin and accelerate the launch of GENinCode’s first product Cardio inCode for the risk assessment of CVD in primary prevention. The EVERSANA group comprises over 4,000 employees. GENinCode specialises in polygenic risk assessment for the onset of cardiovascular disease with the Company’s technology providing clinicians with genetic risk assessment and AI bioinformatics to inform, predict and prevent cardiovascular events. CVD is the leading cause of death and disability worldwide accounting for one in every four deaths in the United States. In 2010, the global cost of CVD was approximately US $863 billion. By 2030, this figure is set to rise to US $1,044 billion and is both a major health issue and global economic burden. CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (causing limb ischaemia, and some chronic kidney disease) and venous thromboembolism. GENinCode will deliver its portfolio of polygenic CVD products through its partnership with EVERSANA. GENinCode and EVERSANA have a vision to inform patients about their cardiovascular risk and to improve public health by using the predictive capability of genomics to assist in making lifestyle choices and targeting treatment to improve patient outcomes. Over the past 15 years GENinCode has amassed significant investment in its research, data, bioinformatics technology and product development to assess disease risk to prevent the onset of CVD. Matthew Walls, CEO, GENinCode said: “We have worked closely with the EVERSANA team over the past 12 months and are delighted to announce our US partnership. EVERSANA provide proven launch and commercialisation expertise to support our market access and will help accelerate our speed to market.” Jim Lang, CEO of EVERSANA said: “GEN inCode’s approach to understanding and addressing genetic risk is revolutionary and as such, these products demand a commercialisation model that bypasses traditionally strategies to acceleration launch, access and impact. EVERSANA is eager to put the full power of our platform to work.” For more information visit www.genincode.com Enquiries: GENinCode UK Limited Tamsin Jeffs Tel +44 (0)7800 903435 EVERSANA Sarah Zwicky Tel +1 (414) 434-4691 About GENinCode GENinCode is a UK based company specializing in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode UK Limited operates business units in Europe and Latin America through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. GENinCode’s predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. To learn more about GENinCode, visit www.genincode.com or connect through LinkedIn and Twitter. About EVERSANA EVERSANA™ is the leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
